×
About 578 results
Gastroesophageal Reflux Disease - StatPearls
https://www.ncbi.nlm.nih.gov/books/NBK441938/
Antunes, C. et. al.

Oct 26th, 2018 - Gastroesophageal reflux disease (GERD) is a condition that develops when there is a retrograde flow of stomach contents causing symptoms or complications. GERD can present as Non-erosive reflux disease (NERD) when typical symptoms of GERD occur in the absence of visible mucosal injury during endoscopy, or as erosive esophagitis (EE) when patients have histopathological changes in esophageal muc...

Asthma as the Underlying Cause of Death | CDC
https://www.cdc.gov/asthma/asthma_stats/asthma_underlying_death.html

Apr 23rd, 2018 - Asthma deaths have decreased over time and varied by demographic characteristics. View the statistics from the Centers for Disease Control and Prevention (CDC) - National Center of Environmental Health (NCEH) - National Asthma Control Program

Topical budesonide effective for eosinophilic esophagitis in pivotal trial
https://www.mdedge.com/internalmedicine/article/211440/gastroenterology/topical-budesonide-effective-eosinophilic?channel=53
Bruce Jancin

Nov 1st, 2019 - SAN ANTONIO – An investigational muco-adherent swallowed formulation of budesonide developed specifically for treatment of eosinophilic esophagitis aced all primary and secondary endpoints in a pivotal, phase 3, double-blind, placebo-controlled randomized trial, Ikuo Hirano, MD, reported at the annual scientific meeting of the American College of Gastroenterology. Dr.

New Treatment Option Emerging for Esophagitis
https://www.medscape.com/viewarticle/920661

Oct 30th, 2019 - SAN ANTONIO — A new option for eosinophilic esophagitis met its primary and key secondary end points in the pivotal phase 3 ORBIT study, the largest trial to date in a therapeutic area with limited treatment choices. Findings from the induction-phase trial of budesonide oral suspension (Takeda) were presented here at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting....

Dupilumab may reduce dysphagia in adults with eosinophilic esophagitis
https://www.mdedge.com/gihepnews/article/210137/upper-gi-tract/dupilumab-may-reduce-dysphagia-adults-eosinophilic?channel=347
Andrew D. Bowser, MDedge News

Oct 15th, 2019 - Dupilumab (Dupixent) significantly reduced patient-reported dysphagia among adults with eosinophilic esophagitis enrolled in a randomized trial, investigators reported. Treatment with this monoclonal antibody also improved histologic disease features and abnormal endoscopic features, compared with placebo, according to investigators in the phase 2 trial, which included 47 patients enrolled at 1.

Dysregulated sleep is common in children with eosinophilic esophagitis
https://www.mdedge.com/clinicianreviews/article/209671/sleep-medicine/dysregulated-sleep-common-children-eosinophilic?channel=296
Michele G. Sullivan

Oct 8th, 2019 - Children with eosinophilic esophagitis often experience respiratory and motor disturbances during sleep, which appear related to dysregulated sleep architecture, Rasintra Siriwat, MD, and colleagues have ascertained. ©Alex Vasilev/Fotolia.

'Chemical Burns' Seen as Possible Cause of Vaping Lung Damage
https://www.medscape.com/viewarticle/919361

Oct 2nd, 2019 - Lung injuries from vaping probably result from direct toxicity or tissue damage caused by noxious chemical fumes, rather than from an accumulation of lipids in the lungs, pathology data suggest. "We were not surprised by what we found, regarding toxicity," Brandon T. Larsen, MD, PhD, a surgical pathologist at the Mayo Clinic, Scottsdale, Arizona, and a national expert in lung pathology, said in...

Upper and lower gastroenterology – the state of the art
https://www.mdedge.com/gihepnews/article/206306/upper-gi-tract/upper-and-lower-gastroenterology-state-art?channel=347
David A. Katzka, MD

Aug 12th, 2019 - In the upper GI section of the Postgraduate course program, Ikuo Hirano, MD, educated us on the refractory patient with eosinophilic esophagitis, reinforcing the need for chronic maintenance treatment and the complementary role of dilation. Gregory Ginsberg, MD, elucidated the specific strategies needed for gastric polyps with advice on which to leave and which to resect.

Preeclampsia doubles risk of postpartum transfusion reactions
https://www.mdedge.com/obgyn/article/205827/obstetrics/preeclampsia-doubles-risk-postpartum-transfusion-reactions?channel=27970
Caleb Rans

Aug 2nd, 2019 - Women with preeclampsia were found to be at the highest risk for transfusion reactions when receiving a blood transfusion post partum, according to results from a retrospective study. Additionally, all women who received a transfusion postpartum were twice as likely to experience a procedure-related complication, compared with nonpregnant controls who received identical care.

Transfusion Reaction Risk Doubled in Postpartum Setting
https://www.medpagetoday.com/obgyn/pregnancy/81387

Aug 2nd, 2019 - The risk of transfusion reactions was twice as high for women requiring blood to treat postpartum hemorrhage compared with nonpregnant women who also required a blood transfusion during the same time period, a Swedish retrospective study showed. Moreover, said Lars Thurn, MD, of Karolinska University Hospital in Stockholm, Sweden, and colleagues, the reactions somewhat paradoxically were more l...

POEM outperforms pneumatic dilation in randomized achalasia trial
https://www.mdedge.com/fedprac/article/205130/gastroenterology/poem-outperforms-pneumatic-dilation-randomized-achalasia?channel=112
Andrew D. Bowser

Jul 22nd, 2019 - In patients with previously untreated achalasia, peroral endoscopic myotomy had a high procedural success rate as compared to pneumatic dilation, results of a randomized clinical trial show. Peroral endoscopic myotomy (POEM) had a success rate exceeding 90%, versus just about 50% for standard balloon dilation in what investigators say is, to their knowledge, the first-ever randomized trial to e.

Peroral Endoscopic Myotomy an Upfront Option for Achalasia
https://www.medscape.com/viewarticle/915414

Jul 9th, 2019 - NEW YORK (Reuters Health) - For the swallowing disorder achalasia, peroral endoscopic myotomy (POEM) provided better symptom control than pneumatic dilation but was associated with more reflux esophagitis in a multicenter randomized controlled trial. "These findings support consideration of POEM as an initial treatment option for patients with achalasia," researchers write in a paper online tod...

Budesonide tablets considerably outperformed placebo for active EoE
https://www.mdedge.com/fedprac/article/203508/gastroenterology/budesonide-tablets-considerably-outperformed-placebo-active?channel=285
Steve Cimino

Jun 25th, 2019 - Budesonide orodispersible tablets (BOTs) are highly effective in inducing disease remission in adults with active eosinophilic esophagitis (EOE), according to a study of the tablets versus placebo in European patients. “A 6-week treatment with 1 mg budesonide twice daily was highly superior over placebo with regard to all predefined primary and secondary outcomes,” wrote Alfredo J.

Budesonide Tablet Tx Promising for EoE
https://www.medpagetoday.com/gastroenterology/generalgastroenterology/78859

Mar 27th, 2019 - Orodispersible budesonide delivered specifically to the esophagus as a tablet was effective in inducing clinical and histological remission in patients with eosinophilic esophagitis (EoE), according to a European randomized, controlled trial. At 6 weeks of treatment, the new topical-acting formulation of the corticosteroid (Jorveza) induced complete clinical/histological remission in about 58% ...

Mucosal impedance contour rapidly distinguished GERD, non-GERD, and eosinophilic esophagitis
https://www.mdedge.com/internalmedicine/article/197667/gastroenterology/mucosal-impedance-contour-rapidly-distinguished?channel=39313
Amy Karon

Mar 27th, 2019 - A balloon catheter system that measures mucosal impedance contour immediately distinguished gastroesophageal reflux disease (GERD), eosinophilic esophagitis, and non-GERD (normal findings), according to the findings of a prospective study of 69 adults. Source: American Gastroenterological Association Each group showed a significantly different (P less than.

PFO Requirements; Catheter Coating Emboli; BASILICA for Leaflet Thrombosis
https://www.medpagetoday.com/cardiology/pci/78724

Mar 21st, 2019 - Among the new operator and institutional requirements for patent foramen ovale (PFO) closure by the Society for Cardiovascular Angiography and Interventions and the American Academy of Neurology: operators should maintain a volume of at least 30 septal interventions (or 15 PFO device placements specifically) every 2 years. (Catheterization and Cardiovascular Interventions) Coating separation in...

Epicutaneous milk immunotherapy can resolve pediatric eosinophilic esophagitis
https://www.mdedge.com/pediatrics/article/195875/asthma/epicutaneous-milk-immunotherapy-can-resolve-pediatric-eosinophilic?channel=39313
Mitchel L. Zoler

Mar 7th, 2019 - SAN FRANCISCO – Clinicians safely used epicutaneous immunotherapy to resolve eosinophilic esophagitis in children and teens secondary to milk consumption in a placebo-controlled, pilot study that included 20 patients. Mitchel L.

Budesonide oral suspension produced ‘modest’ responses in EoE
https://www.mdedge.com/internalmedicine/article/193850/gastroenterology/budesonide-oral-suspension-produced-modest
Amy Karon

Feb 4th, 2019 - Treatment with budesonide oral suspension (BOS) was generally well tolerated and maintained a histologic response in some patients with eosinophilic esophagitis (EoE), according to the results of the 24-week, open-label extension phase of a multicenter, randomized, placebo-controlled, industry-sponsored trial. Rates of histologic response (up to 6 eosinophils per high-power field) were “modest”.

Long-term budesonide oral suspension well tolerated in EoE
https://www.mdedge.com/internalmedicine/article/193850/gastroenterology/long-term-budesonide-oral-suspension-well-tolerated?channel=27970
Amy Karon

Feb 4th, 2019 - Treatment with budesonide oral suspension (BOS) was generally well tolerated and maintained a histologic response in some patients with eosinophilic esophagitis (EoE), according to the results of the 24-week, open-label extension phase of a multicenter, randomized, placebo-controlled, industry-sponsored trial. Rates of histologic response (up to 6 eosinophils per high-power field) were “modest”.